May 7, 2026 04:01PM
Mar 30, 2026 04:01PM
Feb 17, 2026 08:00AM
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Jan 8, 2026 08:00AM
Dec 1, 2025 04:17PM Clear Street Starts Annexon Biosciences (ANNX) at Buy
Nov 10, 2025 04:05PM
Aug 14, 2025 04:05PM
Aug 7, 2025 04:31PM
Aug 7, 2025 04:30PM
Jul 24, 2025 07:00AM
Jul 24, 2025 07:00AM
Jun 18, 2025 04:05PM Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop
May 19, 2025 04:07PM
May 19, 2025 04:05PM
May 12, 2025 08:00AM
May 9, 2025 05:00PM
May 7, 2025 08:00AM
Apr 9, 2025 07:00AM
Apr 8, 2025 04:05PM Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeti
Apr 3, 2025 06:18PM
Mar 3, 2025 08:00AM
Feb 13, 2025 08:30AM
Dec 17, 2024 06:53AM
Dec 16, 2024 07:31AM
Dec 16, 2024 07:30AM
Dec 5, 2024 08:00AM Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Nov 14, 2024 08:00AM
Oct 21, 2024 08:00PM
Oct 15, 2024 08:02AM
Oct 15, 2024 08:00AM
Sep 9, 2024 08:00AM
Aug 13, 2024 09:28AM
Aug 12, 2024 08:00AM Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Aug 5, 2024 08:00AM
Jul 11, 2024 06:09PM
Jun 25, 2024 05:00PM
Jun 25, 2024 05:00PM
Jun 18, 2024 08:00AM
Jun 4, 2024 07:00AM
Jun 4, 2024 07:00AM Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
May 7, 2024 12:30PM
Apr 16, 2024 09:00AM
Mar 26, 2024 04:05PM
Feb 21, 2024 08:00AM
Feb 21, 2024 08:00AM
Dec 20, 2023 05:12PM
Dec 20, 2023 05:10PM Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
Nov 13, 2023 06:31AM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All